Skip to main content
SpringerLink
Log in

Human Papilloma Virus Vaccines

  • Chapter
  • First Online:
Medicines For Women

Abstract

Benign and malignant disease caused by HPV (human papillomavirus) constitutes a global public health problem. Genital warts are the commonest viral sexually transmitted infection and 5 % of all cancers are HPV associated. The unfolding of the HPV story started in the 1970’s with the recognition that HPVs were a large family of viruses that included a subset of types that caused cancer, particularly cancer of the cervix, a disease that kills 250,000 women each year. It has resulted in the development of two prophylactic virus like particle (VLP) vaccines using sophisticated recombinant molecular techniques and protein expression. Both vaccines target infection by the oncogenic HPV’s 16 and 18 and one also targets the low risk HPVs 6 and 11 that cause genital and laryngeal warts. These vaccines are now included in the national immunisation programmes in many countries and population effectiveness in women is being demonstrated in those countries with high vaccine coverage. Since HPV associated cancers in men are increasing in incidence an issue of contemporary debate is extending HPV vaccination to adolescent boys. HPV VLP vaccines have a good safety profile and national and international authorities endorse this. Safety has been assessed in the randomised controlled trials and continues to be monitored by robust pharmacovigilance post licensure using both passive and active vaccine surveillance.

HPV vaccines are highly immunogenic generating serum neutralising antibody that persists for at least 9 years with a robust recall response after antigen challenge at 60 months post vaccination. At present the assumption is that the protection achieved by these vaccines against HPV induced disease is mediated via serum neutralising IgG and this is consistent with what is known of the mechanism of HPV infection in the genital tract. Emerging evidence shows that very low antibody concentrations are protective but at the present there is no immune correlate of protection, disease prevention remains the only measure of the effectiveness of HPV vaccines.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Guy RJ (2013) Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 346:f2032

    Article  PubMed  Google Scholar 

  • Angelo MG, David MP, Zima J, Baril L, Dubin G, Arellano F, Struyf F (2014) Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiol Drug Saf. doi:10.1002/pds.3554 [doi]

    Google Scholar 

  • Baandrup L, Blomberg M, Dehlendorff C, Sand C, Andersen KK, Kjaer SK (2013) Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis 40(2):130–135. doi:10.1097/OLQ.0b013e31827bd66b

    PubMed  Google Scholar 

  • Bonanni P, Cohet C, Kjaer SK, Latham NB, Lambert PH, Reisinger K, Haupt RM (2010) A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD. Vaccine 28(30):4719–4730

    Article  PubMed  Google Scholar 

  • Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Munoz N (2008) Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 26(Suppl 10):K1–K16

    Article  PubMed  Google Scholar 

  • Boxus M, Lockman L, Fochesato M, Lorin C, Thomas F, Giannini SL (2014) Antibody avidity measurements in recipients of Cervarix vaccine following a two-dose schedule or the licensed three-dose schedule. Vaccine. doi:10.1016/j.vaccine.2014.04.005, S0264-410X(14)00507-6 [pii]

    PubMed  Google Scholar 

  • Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, Schiller JT, Lowey DR (1995) Immunization with virus-like particles from cotton tail rabbit papillomavirus (CRPV) can protect against experimentally CRPV infection. J Virol 69:3959–3963

    CAS  PubMed Central  PubMed  Google Scholar 

  • Brown B, Blas M, Cabral A, Carcamo C, Gravitt P, Halsey N (2012) Randomized trial of HPV4 vaccine assessing the response to HPV4 vaccine in two schedules among Peruvian female sex workers. Vaccine 30(13):2309–2314. doi:10.1016/j.vaccine.2012.01.058

    Article  PubMed Central  PubMed  Google Scholar 

  • Buttery JP, Madin S, Crawford NW, Elia S, La Vincente S, Hanieh S, Smith L, Bolam B (2008) Mass psychogenic response to human papillomavirus vaccination. Med J Aust 189(5):261–262

    PubMed  Google Scholar 

  • Callreus T, Svanstrom H, Nielsen NM, Poulsen S, Valentiner-Branth P, Hviid A (2009) Human papillomavirus immunisation of adolescent girls and anticipated reporting of immune-mediated adverse events. Vaccine 27(22):2954–2958

    Article  PubMed  Google Scholar 

  • Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA (2000) Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 181(6):1911–1919

    Article  CAS  PubMed  Google Scholar 

  • Chao C, Jacobsen SJ (2012) Evaluation of autoimmune safety signal in observational vaccine safety studies. Hum Vaccin Immunother 8(9):1302–1304. doi:10.4161/hv.21268, 21268 [pii]

    Article  PubMed Central  PubMed  Google Scholar 

  • Crowe E, Pandeya N, Brotherton JM, Dobson AJ, Kisely S, Lambert SB, Whiteman DC (2014) Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 348:g1458

    Article  PubMed Central  PubMed  Google Scholar 

  • Dana A, Buchanan KM, Goss MA, Seminack MM, Shields KE, Korn S, Cunningham ML, Haupt RM (2009) Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol 114(6):1170–1178

    Article  PubMed  Google Scholar 

  • Denny LA, Franceschi S, de Sanjose S, Heard I, Moscicki AB, Palefsky J (2012) Human papillomavirus, human immunodeficiency virus and immunosuppression. Vaccine 30(Suppl 5):F168–F174. doi:10.1016/j.vaccine.2012.06.045

    Article  CAS  PubMed  Google Scholar 

  • Derkay CS, Darrow DH (2000) Recurrent respiratory papillomatosis of the larynx: current diagnosis and treatment. Otolaryngol Clin North Am 33(5):1127–1142

    Article  CAS  PubMed  Google Scholar 

  • de Villiers EM (2013) Cross-roads in the classification of papillomaviruses. Virology 445(1–2):2–10. doi:10.1016/j.virol.2013.04.023

    Article  PubMed  Google Scholar 

  • Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, Langley JM, Bettinger JA, Singer J, Money D, Miller D, Naus M, Marra F, Young E (2013) Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 309(17):1793–1802. doi:10.1001/jama.2013.1625, 1682939 [pii]

    Article  CAS  PubMed  Google Scholar 

  • Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA (2012) The biology and life-cycle of human papillomaviruses. Vaccine 30(Suppl 5):F55–F70. doi:10.1016/j.vaccine.2012.06.083

    Article  CAS  PubMed  Google Scholar 

  • Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene J, O Flanagan D, Lopalco P, D’Ancona F, Levy-Bruhl D (2010) The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. Euro Surveill 15(47)

    Google Scholar 

  • Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Meric D, Dessy FJ, Datta SK, Descamps D, Dubin G, Group HPVS (2011) Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12–24 in a Phase III randomized study of healthy women aged 18–45 years. Hum Vaccin 7(12):1343–1358. doi:10.4161/hv.7.12.18281

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Esposito S, Birlutiu V, Jarcuska P, Perino A, Man SC, Vladareanu R, Meric D, Dobbelaere K, Thomas F, Descamps D (2011) Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years: results from a randomized study. Pediatr Infect Dis J 30(3):e49–e55. doi:10.1097/INF.0b013e318206c26e

    Article  PubMed  Google Scholar 

  • Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893–2917. doi:10.1002/ijc.25516

    Article  CAS  PubMed  Google Scholar 

  • Garland SM, Skinner SR, Brotherton JM (2011) Adolescent and young adult HPV vaccination in Australia: achievements and challenges. Prev Med 53(Suppl 1):S29–S35. doi:10.1016/j.ypmed.2011.08.015

    Article  PubMed  Google Scholar 

  • Garnett GP (2005) Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 191(1):S97–S106

    Article  PubMed  Google Scholar 

  • Gee J, Naleway A, Shui I, Baggs J, Yin R, Li R, Kulldorff M, Lewis E, Fireman B, Daley MF, Klein NP, Weintraub ES (2011) Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine 29(46):8279–8284. doi:10.1016/j.vaccine.2011.08.106

    Article  PubMed  Google Scholar 

  • Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM (2013) Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 11(1):227. doi:10.1186/1741-7015-11-227

    Article  PubMed Central  PubMed  Google Scholar 

  • Gillison ML, Alemany L, Snijders PJ, Chaturvedi A, Steinberg BM, Schwartz S, Castellsague X (2012) Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine 30(Suppl 5):F34–F54. doi:10.1016/j.vaccine.2012.05.070

    Article  PubMed  Google Scholar 

  • Giuliano AR, Lazcano-Ponce E, Villa L, Nolan T, Marchant C, Radley D, Golm G, McCarroll K, Yu J, Esser MT, Vuocolo SC, Barr E (2007) Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis 196(8):1153–1162

    Article  PubMed  Google Scholar 

  • Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, Chang YH, Ferris D, Rouleau D, Bryan J, Marshall JB, Vuocolo S, Barr E, Radley D, Haupt RM, Guris D (2011) Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 364(5):401–411. doi:10.1056/NEJMoa0909537

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Gold MS, McIntyre P (2010) Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance. Sex Health 7(3):320–324

    Article  PubMed  Google Scholar 

  • Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367(9518):1247–1255

    Article  CAS  PubMed  Google Scholar 

  • Harris T, Williams DM, Fediurek J, Scott T, Deeks SL (2014) Adverse events following immunization in Ontario’s female school-based HPV program. Vaccine. doi:10.1016/j.vaccine.2014.01.004, doi:S0264-410X(14)00005-X [pii]

    Google Scholar 

  • Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, Huh WK, Sings HL, James MK, Haupt RM, for the FI, Group IIS (2012) Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial. Bmj 344:e1401. doi:10.1136/bmj.e1401

    Article  PubMed Central  PubMed  Google Scholar 

  • Kavanagh K, Pollock KG, Potts A, Love J, Cuschieri K, Cubie H, Robertson C, Donaghy M (2014) Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer. doi:10.1038/bjc.2014.198, bjc2014198 [pii]

    Google Scholar 

  • Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT (1992) Papillomavirus L1 major capsid protein self assembles into virus like particles that are highly immunogenic. In: Proceedings of the National Academy of Sciences of the United States of America 89, pp 12180–12184, 24 Dec 15

    Google Scholar 

  • Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, Joura EA, Majewski S, Munoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Maansson R, Lu S, Vuocolo S, Hesley TM, Saah A, Barr E, Haupt RM (2009) A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2(10):868–878. doi:10.1158/1940-6207.CAPR-09-0031

    Article  Google Scholar 

  • Labadie J (2011) Postlicensure safety evaluation of human papilloma virus vaccines. Int J Risk Saf Med 23(2):103–112. doi:10.3233/JRS-2011-0529, V571338816652H47 [pii]

    PubMed  Google Scholar 

  • Lacey CJ, Lowndes CM, Shah KV (2006) Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 24(Suppl 3):S3/35–41

    Google Scholar 

  • Lamontagne DS, Thiem VD, Huong VM, Tang Y, Neuzil KM (2013) Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose. J Infect Dis 208(8):1325–1334. doi:10.1093/infdis/jit363, jit363 [pii]

    Article  CAS  PubMed  Google Scholar 

  • Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, Skinner SR, Apter D, Naud P, Salmeron J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, De Carvalho NS, Germar MJ, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Descamps D, Struyf F, Dubin G (2012) Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13(1):89–99. doi:10.1016/s1470-2045(11)70286-8

    Article  CAS  PubMed  Google Scholar 

  • Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, Unger ER (2013) Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, national health and nutrition examination surveys, 2003–2010. J Infect Dis 208(3):385–393. doi:10.1093/infdis/jit192

    Article  CAS  PubMed  Google Scholar 

  • Mesher D, Soldan K, Howell-Jones R, Panwar K, Manyenga P, Jit M, Beddows S, Gill ON (2013) Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine. doi:10.1016/j.vaccine.2013.10.085

    PubMed Central  PubMed  Google Scholar 

  • Moscicki AB, Wheeler CM, Romanowski B, Hedrick J, Gall S, Ferris D, Poncelet S, Zahaf T, Moris P, Geeraerts B, Descamps D, Schuind A (2012) Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women. Vaccine 31(1):234–241. doi:10.1016/j.vaccine.2012.09.037

    Article  CAS  PubMed  Google Scholar 

  • Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM (2010) Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on All HPV-associated genital diseases in young women. J Natl Cancer Inst 102(5):325–339

    Article  CAS  PubMed  Google Scholar 

  • Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, Iversen OE, Hoye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, von Krogh G, Lehtinen M, Paavonen J, Tamms GM, Giacoletti K, Lupinacci L, Esser MT, Vuocolo SC, Saah AJ, Barr E (2007) Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25(26):4931–4939

    Article  CAS  PubMed  Google Scholar 

  • Pagliusi SR, Teresa Aguado M (2004) Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 23(5):569–578, Dec 16

    Article  PubMed  Google Scholar 

  • Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, Marshall JB, Radley D, Vuocolo S, Haupt RM, Guris D, Garner EI (2011) HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 365(17):1576–1585. doi:10.1056/NEJMoa1010971

    Article  CAS  PubMed  Google Scholar 

  • Parkin DM, Bray F (2006) Chapter 2: the burden of HPV-related cancers. Vaccine 24(Suppl 3):S3/11–25

    Google Scholar 

  • Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK (2011) The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 87(7):544–547. doi:10.1136/sextrans-2011-050234

    Article  PubMed  Google Scholar 

  • Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, Puchalski D, Giacoletti KE, Sings HL, Lukac S, Alvarez FB, Barr E (2007) Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 26(3):201–209

    Article  PubMed  Google Scholar 

  • Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, Choyke PL, Lowy DR, Schiller JT (2007) Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 13(7):857–861

    Article  CAS  PubMed  Google Scholar 

  • Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Catteau G, Dobbelaere K, Schuind A, Descamps D (2011) Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin 7(12):1374–1386. doi:10.4161/hv.7.12.18322

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Roteli-Martins C, Naud P, De Borba P, Teixeira J, De Carvalho N, Zahaf T, Sanchez N, Geeraerts B, Descamps D (2012a) Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother 8(3):390–397

    Article  PubMed  Google Scholar 

  • Roteli-Martins CM, Naud P, De Borba P, Teixeira JC, De Carvalho NS, Zahaf T, Sanchez N, Geeraerts B, Descamps D (2012b) Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother 8(3):390–397. doi:10.4161/hv.18865, 18865 [pii]

    Article  PubMed  Google Scholar 

  • Rowhani-Rahbar A, Mao C, Hughes JP, Alvarez FB, Bryan JT, Hawes SE, Weiss NS, Koutsky LA (2009) Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine 27(41):5612–5619

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Rowhani-Rahbar A, Alvarez FB, Bryan JT, Hughes JP, Hawes SE, Weiss NS, Koutsky LA (2012) Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine. J Clin Virol 53(3):239–243. doi:10.1016/j.jcv.2011.12.009

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Schiller JT, Castellsague X, Garland SM (2012) A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30(Suppl 5):F123–F138. doi:10.1016/j.vaccine.2012.04.108

    Article  CAS  PubMed  Google Scholar 

  • Shope RE (1937) Immunization of rabbits to infectious papillomatosis. J Exp Med 65:607–624

    Article  Google Scholar 

  • Siegrist CA, Lewis EM, Eskola J, Evans SJ, Black SB (2007) Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J 26(11):979–984

    Article  PubMed  Google Scholar 

  • Silverberg MJ, Thorsen P, Lindeberg H, Grant LA, Shah KV (2003) Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol 101(4):645–652

    Article  PubMed  Google Scholar 

  • Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, Izurieta HS, Ball R, Miller N, Braun MM, Markowitz LE, Iskander J (2009) Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 302(7):750–757

    Article  CAS  PubMed  Google Scholar 

  • Stanley M (2008) Immunobiology of HPV and HPV vaccines. Gynecol Oncol 109(2 Suppl):S15–S21

    Article  CAS  PubMed  Google Scholar 

  • Stanley M, Lowy DR, Frazer I (2006) Chapter 12: prophylactic HPV vaccines: underlying mechanisms. Vaccine 24(Suppl 3):S3/106–113

    CAS  Google Scholar 

  • Suzich JA, Ghim SJ, Palmer Hill FJ, White WI, Tamura JK, Bell JA, Newsome JA, Jenson AB, Schlegel R (1995) Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A 92(25):11553–11557, Dec 5

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, Bateson D, McNamee K, Garefalakis M, Garland SM (2012) Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 206(11):1645–1651. doi:10.1093/infdis/jis590

    Article  PubMed  Google Scholar 

  • Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, Brown DR, Ferenczy A, Harper DM, Koutsky LA, Kurman RJ, Lehtinen M, Malm C, Olsson SE, Ronnett BM, Skjeldestad FE, Steinwall M, Stoler MH, Wheeler CM, Taddeo FJ, Yu J, Lupinacci L, Railkar R, Marchese R, Esser MT, Bryan J, Jansen KU, Sings HL, Tamms GM, Saah AJ, Barr E (2006) Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 24(27–28):5571–5583, Jul 7

    Article  CAS  PubMed  Google Scholar 

  • Winer RL, Feng Q, Hughes JP, O’Reilly S, Kiviat NB, Koutsky LA (2008) Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis 197(2):279–282

    Article  PubMed Central  PubMed  Google Scholar 

  • Woodhall SC, Jit M, Cai C, Ramsey T, Zia S, Crouch S, Birks Y, Newton R, Edmunds WJ, Lacey CJ (2009) Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom. Sex Transm Dis 36(8):515–521

    Article  PubMed  Google Scholar 

  • Zhou J, Sun XY, Stenzel DJ, Frazer IH (1991) Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion like particles. Virology 185(1):251–257

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QP, UK

    Margaret Stanley

Authors
  1. Margaret Stanley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Margaret Stanley .

Editor information

Editors and Affiliations

  1. Dean’s Department, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

    Mira Harrison-Woolrych

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Stanley, M. (2015). Human Papilloma Virus Vaccines. In: Harrison-Woolrych, M. (eds) Medicines For Women. Adis, Cham. https://doi.org/10.1007/978-3-319-12406-3_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-12406-3_9

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-12405-6

  • Online ISBN: 978-3-319-12406-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation